Novo Nordisk's obesity and diabetes drugs to be investigated for psychological side effects
The EMA is investigating whether suicidal thoughts could be a side effect of treatment with Novo’s weight-loss treatments.
by ritzau
The active ingredients semaglutide and liraglutide, which are used in several of Novo Nordisk’s obesity and diabetes drugs, are being investigated for serious psychological side effects by the European Medicines Agency (EMA).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
